Taltz ® (ixekizumab) injection

80 mg/mL

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

How many patients relapsed following discontinuation of TALTZ® (ixekizumab) for psoriasis?

For ixekizumab responders at Week 12 who were re-randomized to treatment withdrawal (i.e., placebo), the median time to relapse was 164 days.

Detailed Information

  • For the analyses summarized below, response was defined as a sPGA score of 0 (clear skin) or 1 (minimal) and relapse was defined as a sPGA score of >3.1

  • In 2 phase 3 clinical trials, patients who were originally randomized to ixekizumab and who responded to treatment at week 12 were re-randomized to an additional 48 weeks of ixekizumab 80 mg Q4W or placebo.1

  • In those week 12 responders to ixekizumab who were re-randomized to treatment withdrawal (ie, placebo), 7% maintained their clinical response at week 60. The median time to relapse was 164 days.1

  • In responders who were re-randomized to treatment with ixekizumab Q4W, 75% maintained their response at week 60.1

  • Detailed clinical trial design information is available upon request.

Enclosed Prescribing Information

TALTZ® (ixekizumab) injection, for subcutaneous administration, Lilly

Reference

1. Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.

Glossary

Q4W = every 4 weeks

sPGA = static Physician Global Assessment

Date of Last Review: September 17, 2018

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 8am - 7pm ET

Or you can

Ask us a question Chat with us

Submit a Request

Visit Us @LillyMedical